This report describes a salivary duct carcinoma (SDC) arising from the extraglandular portion of the Stensen duct. The patient was a 56-year-old man who presented with a palpable, elastic, hard mass without tenderness in the right cheek. Computed tomography revealed a tumor of the extraglandular portion of the Stensen duct. Supraomohyoid right neck dissection and total right parotidectomy were performed, and the histologic diagnosis was SDC of the Stensen duct. Postoperatively, the patient received no additional treatment. Neither recurrence nor metastasis was observed during 4 years of follow-up examination. SDC of the Stensen duct is extremely rare. To our knowledge, there is no report that describes primary SDC arising from that location. We also believe this is the first report that describes the clinical course of primary SDC arising from a Stensen duct.
Introduction
Salivary duct carcinoma (SDC) is an aggressive, malignant salivary gland tumor that was first reported by Kleinsasser et al in 1968. 1 They considered SDC to be analogous to ductal carcinoma of the breast. SDC is usually seen in patients >50 years of age and is three times more frequent in men than in women. 2, 3 Clinically, it is characterized by a severe clinical course, with a high incidence of local recurrence, lymph node and distant metastasis, and a low survival rate. 3, 4 When it occurs in the head and neck region, the most frequent location is the parotid glands (88%), followed by the submandibular (8%) or minor (4%) salivary glands. 5 To the best of our knowledge, this report presents for the first time a case of primary SDC that arose from a Stensen duct and describes its clinical course.
Case report
A 56-year-old man presented with swelling in the right cheek in November 2006. An elastic and hard mass without tenderness was palpable in the right cheek. Lymph node swelling and facial palsy were not observed. He had no clinical history of right parotiditis. Secretion of saliva from the right orifice of the Stensen duct was decreased compared with that from the left orifice. Bougienage into the right Stensen duct from its orifice was obstructed at the site of the mass.
Computed tomography (CT) of the patient's neck showed a 25-mm, heterogeneous tumor without clear borders anterior to the right masseter muscle (figure 1). The tumor showed low signal intensity on T1-weighted magnetic resonance (MR) images and high signal intensity on T2-weighted MR images. Contrast-enhanced T1-weighted images showed strong enhancement of the tumor (figure 2). Fine-needle aspiration of the tumor was performed, and the cytologic findings were suggestive of adenocarcinoma. After informed consent was obtained, supraomohyoid right neck dissection and total right parotidectomy were performed under general anesthesia. The tumor was adjacent to the right zygomatic branches of the facial nerve and masseter muscle. The zygomatic branches were transected, and the part of the masseter muscle adjacent to the tumor was excised together with the tumor. Macroscopically, the location of the tumor was the extraglandular portion of the Stensen duct (figure 3).
Intraoperative frozen section diagnosis of the resection stump of the Stensen duct revealed no malignancy. Histologic examination of the resected specimens revealed that the tumor extended along the luminal epithelium of the extraglandular portion of the Stensen duct, and the tumor was retained in the lumen of the duct. There were no tumor cells in the right parotid gland and no lymph node metastasis. The tumor showed ductal, cribriform, papillary, and cystic growth patterns characteristic of SDC.
Comedo-like necrosis was also observed. The tumor was positive for gross cystic disease fluid protein-15 (GCDFP-15) and human epidermal growth factor receptor type 2 (HER-2) by immunohistochemical staining. The histologic diagnosis was an SDC of the Stensen duct ( figure 4 ). In the resection stump of the excised specimen, tumor cells were found in the lumen of the duct, although the luminal epithelium showed no cytologic atypia.
Considering the possibility of incomplete surgical excision of the tumor, additional surgery was performed, and the residual right Stensen duct and surrounding scar tissue were excised. The histologic examination revealed that there were no tumor cells in the residual Stensen duct and surrounding tissues. The patient refused postoperative radiation therapy and chemotherapy and received no further treatment after surgery. Neither recurrence nor metastasis was observed during 5 years of follow-up.
Discussion
In 1968, Kleinsasser et al described five salivary gland tumors considered to be morphologically similar to ductal carcinomas of the breast, which they termed analogously as salivary duct carcinoma. 1 Pathologically, SDC is characterized by an intraductal component of dysplastic ductal cells that grow in solid, cribriform, and papillary configurations, often with comedo-like central necrosis and by an invasive component consisting of irregular glands and cords of compressed cells with dense fibrous stroma. The tumor cells are cuboidal and polygonal with eosinophilic cytoplasm and show cytologic features of malignancy, such as cellular and nuclear pleomorphism, nuclear hyperchromatism, and mitotic figures. 6 In the present case, the resected specimen clearly revealed that SDC with typical histologic findings occupied the extraglandular portion of the Stensen duct.
Immunohistochemically, SDC is frequently positive for GCDFP-15 and androgen receptor (AR). 7 The expres- PRIMARY SALIVARY DUCT CARCINOMA ARISING FROM THE STENSEN DUCT sion of HER-2 is an indicator of the aggressive behavior and metastatic potential of SDC. 8 In the present case, the SDC was positive for GCDFP-15 and HER-2, although it stained negatively for AR.
SDC of the Stensen duct is extremely rare. To the best of our knowledge, this is the first report that describes the clinical course of primary SDC arising from a Stensen duct.
SDC occasionally arises in a pleomorphic adenoma (PA). Lewis et al 4 and Delgado et al 6 reported that preexisting PA was observed in 23% and 20%, respectively, of cases of SDC. One case of SDC ex-PA of a Stensen duct has been reported in the English literature. 6 In that case, the patient underwent total parotidectomy and radiotherapy. Neither recurrence nor metastasis was observed during the fifth-year follow-up examination after surgery.
Another important finding of this report is our patient's excellent postoperative course. Clinically, SDC is a highly malignant tumor characterized by extensive cervical lymph node (77%) and distant (62%) metastasis with a high rate of recurrence (35%). 4 The most effective therapy for SDC is complete surgical excision followed by radiation therapy. Because of the high incidence of regional lymph node metastasis during the course of the disease, treatment of the cervical lymph nodes, either by neck dissection or irradiation, should be accomplished even if the neck appears clinically negative. 5 For local control of SDC recurrence, postoperative radiation therapy has been recommended. 9 In the present case, supraomohyoid right neck dissection and total right parotidectomy were performed, but additional treatment, including radiation therapy, was not carried out, and neither recurrence nor metastasis was observed during 5 years of follow-up.
As mentioned earlier, SDC is considered by some to be morphologically similar to ductal carcinoma of the breast. 1 Most cases of intraductal carcinoma of the breast do not recur or become invasive when treated by excision alone. 10 In the present case, the tumor was retained in the lumen of the Stensen duct, and there was no sign of recurrence or metastasis during the 5-year follow-up period.
When SDC of a Stensen duct is retained in the lumen, it might have a lower incidence of recurrence and metastasis than is seen with the parotid gland, although a Stensen duct is not morphologically identical to a breast duct. This might further highlight the importance of complete surgical excision in the treatment of SDC arising from a Stensen duct; however, SDC is a tumor of high malignancy, and a strict 5-year follow-up regimen must be continued postsurgically. 
